Samsung Biologics gets full custody over Samsung Bioepis
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Samsung Biologics said Friday it is acquiring 49 percent of Samsung Bioepis from Biogen for $2.3 billion, making the biosimilar company its wholly-owned subsidiary.
Established in 2012 as a joint venture of Samsung Biologics and Biogen, Samsung held 51 percent of the biosimilar company while the Cambridge, Massachusetts-based company held the remaining 49 percent.
The deal this time around was made upon Biogen’s request, Samsung said, and the payment will be made over the next two years.
Samsung Biologics is planning to secure the funds by issuing new shares worth 3 trillion won ($2.5 billion).
“By holding 100 percent of Samsung Bioepis, Samsung Biologics will be able to acquire all of the accumulated technology and capacity the biosimilar company owns in all process including developing drugs, conducting clinical trials, gaining approvals and marketing," the Songdo, Incheon-based biopharmaceutical company said in Friday's release. "Samsung and Biogen will continue close cooperation even after the deal's conclusion."
Samsung Bioepis has a total of 10 biosimilar products and candidates. Five — three autoimmune treatments and two oncology treatments — are being used globally, and one product is set to be introduced within the first half after acquiring approvals last year from the U.S. Food and Drug Administration (FDA) and European Commission. Four candidates are currently undergoing Phase 3 clinical trials.
Biosimilars, according to the FDA, are products that are approved based on proof that they are highly biologically similar to other FDA-approved products. The drugs have no clinically meaningful differences in terms of safety or effectiveness from the reference product, but they cost less.
The global market for biosimilars, which was around $10 billion in 2021, is expected to grow to $22 billion in 2030.
Samsung Biologics rose 3.8 percent to close at 739,000 won Friday.
BY SARAH CHEA [chea.sarah@joongang.co.kr]
Copyright © 코리아중앙데일리. 무단전재 및 재배포 금지.
- Luxury, lies and life with a 'gold spoon'
- Former idols return to the stage to show moms can do it all
- Several more YG Entertainment acts test positive for Covid-19
- Samsung had record sales in 2021, underwhelming profit
- JYP Entertainment unveils name of new girl group set to debut in February
- YouTuber Song Ji-ah posts apology video, turns channel private
- Int'l students urged to get vaccinated before arriving
- A guide to Seollal's must-eat dish
- Son, Hwang and Park discuss Premier League camaraderie
- The little airlines that could hope to take on very big routes